fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Alarm over lax oversight of weight loss drug ads that could harm patients

Written by | 19 Dec 2023

UK organisations responsible for protecting the public from prescription-only drug adverts are putting patients at risk from the harms of weight loss drugs by not enforcing the law,… read more.

MHRA (UK) expands approval for Xeomin to treat focal spasticity of the lower limbs affecting the ankle joint – Merz Therapeutics

Written by | 16 Jun 2023

The MHRA (UK) has granted approval for a new indication for Merz Therapeutics’ Xeomin (incobotulinumtoxinA) to treat focal spasticity of the lower limbs affecting the ankle joint. The… read more.

UK government media releases risk flouting regs on promotion of prescription only meds

Written by | 30 Sep 2022

Recent media releases/statements on new prescription medicines (POMs) issued by the UK Department of Health and Social Care and its executive NHS agencies, risks flouting the strict regulations… read more.

UK rolls out new drug approval pathway

Written by | 12 Feb 2022

Effective 1 January 2022 Pharmaceutical companies can now seek accelerated drug approvals in the UK using the newly launched Innovative Licensing and Access Pathway (ILAP). The new approval… read more.

Molnupiravir – what you need to know

Written by | 10 Dec 2021

Molnupiravir has been approved by the MHRA for early treatment of mild-moderate covid-19 in vulnerable adults, it was announced on 4th November. It is good news that at… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.